BrightHeart has raised €11 million ($12.8 million) in funding to advance commercialization efforts for its artificial intelligence (AI)-based prenatal congenital heart defect (CHD) screening platform.
The French company's B-Right platform uses AI to identify structural markers suggestive of CHD from second-trimester fetal ultrasound images. The platform received U.S. Food and Drug Administration (FDA) clearance in November 2024. In 2025, Brightheart received additional approval for software that allows healthcare professionals to access B-Right analytics in real-time via a cart-side tablet.
Discover effective B2B marketing
We combine business intelligence and editorial excellence to reach passionate professionals across 36 major media platforms.
learn more
Brightheart plans to use the funding to expand B-Right's presence across U.S. healthcare facilities. As of 2025, the platform is used in a limited range of facilities, including Mount Sinai Hospital in New York.
Brightheart's Series A funding round was co-led by venture capital (VC) firms Odyssée Venture and GO Capital, with participation from other investors including Mussallem CHD Alliance, Lift Value, and founding investor Sofinnova Partners.
BrightHeart CEO Cecile Dupont commented, “This new round of funding allows us to accelerate BrightHeart's mission to make AI the new standard of care for prenatal ultrasound. Our goal is to increase diagnostic accuracy, improve outcomes for families and babies, and streamline clinical workflows for healthcare professionals.”
In January 2025, Brightheart presented data from two studies at the 2025 Society for Maternal-Fetal Medicine (SMFM) Pregnancy Conference in Colorado. A study of 200 prenatal ultrasound data sets revealed that BrightHeart's AI software increased sensitivity by 15.3% and improved detection rates. The software also improved efficiency, reducing expert reading time by 18%.
Research shows that CHD affects 1 in 100 births worldwide. However, 70% of cases require treatment within the first year of life, and more than 90% of cases in low- and middle-income countries are untreated or receive suboptimal treatment.
Although minimally invasive techniques have steadily advanced in recent years, the most common approach to correcting CHD is open-heart surgery, according to a GlobalData analysis.
AI is having a strong impact in healthcare, with GlobalData's analysis predicting that the valuation of AI in healthcare will reach $19 billion by 2027.
BrightHeart is one of many companies leveraging AI in medical imaging, one of the most prominent areas of technology adoption in healthcare. talk to medical device network In 2025, DeepLook Medical CEO Marissa Fayer said the potential applications of AI in image processing are “limitless.”
In 2025, HeartFlow, developer of an AI-based platform to more accurately assess patients with arterial plaque buildup (atherosclerosis), completed a $364 million initial public offering (IPO). Observers say the success of the U.S. company's IPO reflects “full validation” of AI by the market.
